View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 24, 2021

Appili concludes subject enrolment in Phase III Covid-19 drug trial

In November 2020, Appili commenced the trial for evaluating oral Avigan/Reeqonus as a potential at-home treatment for Covid-19.

Appili Therapeutics has concluded subject enrolment in its international Phase III PRESECO clinical trial of oral Avigan/Reeqonus (favipiravir) as a potential drug for Covid-19.

The trial enrolled 1,231 subjects from 38 trial centres across the US, Mexico, and Brazil.

Developed by Fujifilm Toyama Chemical, Avigan/Reeqonus is a broad-spectrum oral antiviral drug.

It specifically hinders viral RNA-dependent ribonucleic acid (RNA) polymerase (sRdRP) with potent antiviral activity against single-stranded RNA viruses such as coronaviruses.

The company raised the enrolment targets to increase the number of patients and SARS-CoV-2 variant cases, including Delta variant, in the trial.

Appili commenced the trial in November 2020 to assess oral Avigan/Reeqonus as a potential at-home treatment for Covid-19.

The double-blind, placebo-controlled, randomised, multicentre Phase III superiority trial is assessing the safety and efficacy of oral Avigan/Reeqonus as the early therapy for adult Covid-19 patients with mild-to-moderate symptoms.

Participants will comprise outpatients who were tested positive for Covid-19 within 72 hours of recruitment.

Subjects in the trial will administer the drug themselves in the at-home setting and the trial investigators will monitor them remotely.

The impact of oral antiviral on time to Covid-19 symptom resolution will be the primary goal of the trial.

Furthermore, the trial will assess the impact of the drug on disease progression to severe Covid-19.

It also comprises a viral shedding sub-study, which is analysing the impact of Avigan/Reeqonus on time to viral clearance.

Last week, Appili completed subject enrolment in the viral shedding sub-study portion of Avigan/Reeqonus in the US.

In addition, viral isolates will be sequenced for detecting SARS-CoV-2 variants in the PRESECO trial.

Appili Therapeutics CEO Armand Balboni said: “Completing enrolment in this large Phase III pivotal trial in just ten months is a tremendous accomplishment for Appili.

“With this major milestone now achieved, we have a clear path to completing the PRESECO data analysis in the coming weeks and determining if Avigan/Reeqonus has the potential to meet the urgent global clinical need for a safe and effective oral treatment for this deadly disease.”

Top-line results from the trial are expected in nearly 60 days.

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy